LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products and therapies for neurological and cardiac conditions worldwide. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related accessories. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; and devices that deliver neuromodulation therapy for treating difficult-to-treat depression and drug-resistant epilepsy. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its medical devices through a combination of direct sales representatives, agents, and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.

Period	PE Ratio
2016-12-31	-57.23
2017-12-31	-141.98
2018-12-31	-18.88
2019-12-31	-23.00
2020-12-31	-10.40
2021-12-31	-27.55
2022-12-31	-45.86
2023-12-31	223.73
2024-12-31	63.10
2025-12-31	-16.59

	A	B	C	D
1	Symbol	Price	Change	Volume
2	LIVN	$73.83	+0.26%	0.42M
3
4
5

LivaNova PLC (LIVN) PE Ratio

PE Ratio Data

Get LivaNova PLC Data in Excel

More LIVN Financial Data